A medical research study to evaluate the safety and effectiveness of two investigational medications for vitiligo
Phase 1
Active, not recruiting
- Conditions
- VitiligoMedDRA version: 20.0Level: PTClassification code 10047642Term: VitiligoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- EUCTR2018-001271-20-ES
- Lead Sponsor
- Pfizer Inc 235 East 42nd Street, New York, NY10017 US
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 364
Inclusion Criteria
- Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.
- Must have moderate to severe active non-segmental vitiligo.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 660
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0
Exclusion Criteria
- History of human immunodeficiency virus (HIV) or positive HIV serology at screening.
- Infected with hepatitis B or hepatitis C viruses.
- Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method